Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
@HOME: Dapagliflozin Individual Response in T2DM
NCT06374043Phase 4Completed
- Sponsor
- University Medical Center Groningen
- Start
- May 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), sponsored by University Medical Center Groningen. Started May 2021; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06374043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06374043.